Merck & Co., Inc., Rahway, NJ, USA (United States)
Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.
Driven by 2 papers. Top paper: “Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer”.
Delvys Rodríguez-Abreu, Andrew G. Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp +16 more
Paul Baas, Dong-Wan Kim, Enriqueta Felip, José L Pérez-Gracia, Ji-Youn Han +20 more